Online EBSA courses 2020
2020 - online program
|15 October, 11:00 – 13:00 CET||Biological risk assessment: How safe are we in our labs if we apply the risk based approach according to the new WHO Biosafety Manual? - The course with simultaneous translation into Ukrainian language is supported by the German Biosecurity Program (sold out)|
|22 October, 11:00 – 13:00 CET|
|27 October, 10:00 - 14:00 CET||Blend your Biosafety Training -
How to produce and use educational technologies
|3 November 10:00- 14:30 CET||ISO 35001 – An introduction into the biorisk management standard|
|5 November 10:00- 14:30 CET||ISO 35001 – An introduction into the biorisk management standard - The course with simultaneous translation into Ukrainian language is supported by the German Biosecurity Program (sold out)|
|12 November, 10:00 - 15:30 CET
13 November, 10:00 - 12:00 CET
|Gene therapy: main approaches and biosafety issues|
|18 November 13:30- 15:30 CET||Biological risk assessment: How safe are we in our labs if we apply the risk based approach according to the new WHO Biosafety Manual? - Course in French. Supported by German Biosecurity Program. Sold out|
|18 January||ISO 35001 – An introduction into the biorisk management standard - Course in French. Supported by German Biosecurity Program. Sold out|
Biological Risk Assessment – How safe are we in our labs if we apply the risk based approach according to the new WHO Biosafety Manual?
Instructor: Kathrin Summermatter
Moderator: Heather Sheeley
Managing biological risks in various environments in which hazardous biological materials are used, be it in research, diagnostic, production facilities or animal units is of utmost importance. Biosafety professionals very often play the interface between different stakeholders such as scientists, engineering, maintenance or cleaning staff.
During the COVID-19 pandemic, biosafety professionals were constantly challenged and had to apply the risk based approach again and again nearly on a daily basis. Initial risk assessments for activities in the diagnostic laboratory had to be adapted to the new conditions (e.g. shortage of safety equipment) and at the same time the safety of all laboratory staff had to be ensured.
How can we deal with the increased workload during thee COVID-19 pandemic and at the same time guarantee the safety of our employees?
In this webinar these and other questions will be addressed by using the risk based approach of the new WHO biosafety manual.
7.2.3 Biological and other hazards in the work area
7.2.7 Biorisk assessment and management
Blend your biosafety training - how to produce and use educational technologies
Instructors: Henrik Bregnhøj, Lawrence Dickson
This half-day course will give you an introductory experience with application of current digital educational technologies like production and use of power point-based videos, planning and execution of webinars, and the use of an Learning Management System in your teaching.
ISO 35001 – An introduction into the biorisk management standard
The ISO 35001 standard on “Biorisk management for laboratories and other related organisations - is the first internationally recognized management standard to specifically address hazards associated with laboratories where biological materials are handled at all containment levels. It sets out the requirements for a management system to enable organizations to effectively identify, monitor, and control risk associated with laboratory biosafety and biosecurity. It also provides a structured approach to managing risk associated with people, facilities and working procedures in laboratory environments.
The Biorisk management standard is a compendium of all biosafety and biosecurity issues irrespectively of actual laws or administrative provisions. It defines key requirements encompassing all relevant laws and does not focus on the application of individual pieces of legislation. Therefore, the ISO 35001 standard is deliberately general in order to accommodate national differences.
The ISO 35001 webinar aims to help you understand the fundamentals of the standard and how it can be applied to your organization. It will present the principles of biorisk management, identify the multiple components of a biorisk programme and explore ways to integrate them into the management system(s) in place or to be developed in an institution.
The course participants will be able to
The learning objectives are in line with CWA 16335:2011 on the Biosafety Professional, specifically with the CWA clause 7.2.17., “The biosafety professional shall be able to develop and support the implementation of a biorisk management programme and understand how the elements (e.g. physical, personal and informational biosecurity measures) in such a programme are interrelated so as to achieve the objectives of the programme. The biosafety professional shall be able to understand and apply the core principles and practices associated with a management system approach that incorporates continual improvement and be able to communicate them.”
3 November 10:00 - 14:30 CET
(lunch break 11:30 - 13:00)
Gene therapy: main approaches and biosafety issues
Though the idea for gene therapy was put forward in 1972, it was not until 2003 in China and 10 years later in US, that DNA drug actually appeared on the market. Since then, at least nine gene therapies have been approved for a few cancer types, genetic disorders and viral infections and a great number of research projects and clinical trials are underway in many countries.
At the end of the course, participants should be able to:
The training will focus on:
Participants will have the opportunity to perform a team-work risk assessment on case studies corresponding to current clinical trials.
CWA 15793 Reference